Article
Oncology
Amr Mohamed, Renjian Jiang, Philip A. Philip, Maria Diab, Madhusmita Behera, Christina Wu, Olatunji Alese, Walid L. Shaib, Tyra M. Gaines, Glen G. Balch, Bassel F. El-Rayes, Mehmet Akce
Summary: This study evaluated the prognostic value of high-risk features in proficient mismatch repair stage II colon cancer patients, finding that these features were associated with shorter overall survival and that adjuvant chemotherapy may benefit patients aged 65 and older with high-risk features.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Meridith C. Ginesi, Jonathan T. Bliggenstorfer, Daphine M. Kwesiga, Samantha H. Xu, Diana Jodeh, J. Eva Selfridge, Sharon L. Stein, Emily F. Steinhagen
Summary: This study investigated the use of chemotherapy and its impact on survival in stage II colon cancer patients. It found that factors associated with not receiving chemotherapy in high-risk patients included increasing age, distance from the treatment facility, Charlson-Deyo score, and lack of insurance. Chemotherapy was associated with improved overall survival, but only high-risk patients benefited from it.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Jeanne Tie, Joshua D. Cohen, Kamel Lahouel, Serigne N. Lo, Yuxuan Wang, Suzanne Kosmider, Rachel Wong, Jeremy Shapiro, Margaret Lee, Sam Harris, Adnan Khattak, Matthew Burge, Marion Harris, James Lynam, Louise Nott, Fiona Day, Theresa Hayes, Sue-Anne McLachlan, Belinda Lee, Janine Ptak, Natalie Silliman, Lisa Dobbyn, Maria Popoli, Ralph Hruban, Anne Marie Lennon, Nicholas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein, Cristian Tomasetti, Peter Gibbs
Summary: This study found that using ctDNA results to guide treatment decisions for stage II colon cancer reduced the use of adjuvant chemotherapy without compromising recurrence-free survival.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Nancy N. Baxter, Erin B. Kennedy, Emily Bergsland, Jordan Berlin, Thomas J. George, Sharlene Gill, Philip J. Gold, Alex Hantel, Lee Jones, Christopher Lieu, Najjia Mahmoud, Arden M. Morris, Erika Ruiz-Garcia, Y. Nancy You, Jeffrey A. Meyerhardt
Summary: The study aims to develop recommendations for adjuvant therapy for patients with resected stage II colon cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Peng Zheng, Yang Lv, Yihao Mao, Feifan Shen, Zhiyuan Zhang, Jiang Chang, Shanchao Yu, Meiling Ji, Qingyang Feng, Jianmin Xu
Summary: This study evaluated the clinical implications of CUL9 expression in colon cancer patients, particularly its prognostic and predictive value for postoperative adjuvant chemotherapy. The results showed that high CUL9 expression was an independent prognostic factor for survival outcomes and could help identify high-risk patients who would benefit from standard 6-month chemotherapy regimens.
Article
Oncology
Xin Chen, Junhao Tu, Xiaolan Xu, Wen Gu, Lei Qin, Haixin Qian, Zhenyu Jia, Chuntao Ma, Yinkai Xu
Summary: This study found that adjuvant chemotherapy in elderly patients with stage III colon cancer can reduce cancer-specific mortality rate, but the benefit of chemotherapy in stage II colon cancer patients is suboptimal.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Yasmeen Z. Qwaider, Naomi M. Sell, Caitlin E. Stafford, Hiroko Kunitake, James C. Cusack, Rocco Ricciardi, Liliana G. Bordeianou, Vikram Deshpande, Robert N. Goldstone, Christy E. Cauley, David L. Berger
Summary: This study found that infiltrating TBC is a high-risk factor in patients with stage II and III colon adenocarcinoma. Patients with stage II disease and infiltrating TBC, who are node-negative, should be considered for adjuvant chemotherapy.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Yuanyuan Chen, Mingyue Xu, Qianwen Ye, Jia Xiang, Tianhui Xue, Tao Yang, Long Liu, Bing Yan
Summary: Irregular delay of adjuvant chemotherapy (IDacT) has a significant impact on the prognosis of stage II-III colorectal cancer (CRC) patients, and the effect of delay per cycle (DpC) is more pronounced, resulting in significantly worse disease-free survival (DFS) for patients with longer DpC.
Article
Multidisciplinary Sciences
Ailin Qu, Qian Wang, Qing Chang, Jingkang Liu, Yongmei Yang, Xin Zhang, Yanli Zhang, Xiaoshi Zhang, Hongchun Wang, Yi Zhang
Summary: By analyzing tissue samples from stage II colon cancer patients, we developed a predictive model based on long non-coding RNA (lncRNA) to improve the accuracy of prognosis prediction. This model consists of 11 lncRNAs and can categorize patients into high-risk and low-risk groups. It has independent predictive value and stronger prognostic ability compared to current clinical risk factors. The model can facilitate personalized treatment decisions and postoperative counseling, ultimately leading to improved survival.
SCIENTIFIC REPORTS
(2023)
Article
Gastroenterology & Hepatology
Brendan L. Hagerty, John G. Aversa, Dana A. Dominguez, Jeremy L. Davis, Jonathan M. Hernandez, James T. McCormick, Andrew M. Blakely
Summary: In patients with stage II colon cancer, young patients frequently receive adjuvant chemotherapy while older patients rarely receive adjuvant therapy. Age is an independent factor associated with the receipt of adjuvant chemotherapy.
DISEASES OF THE COLON & RECTUM
(2022)
Article
Oncology
Lana Khalil, Xingyu Gao, Jeffrey M. Switchenko, Olatunji B. Alese, Mehmet Akce, Christina Wu, Maria Diab, Bassel F. El-Rayes, Walid L. Shaib
Summary: This age group-based study examines the impact of adjuvant therapy in patients older than 70 with colon cancer. The study suggests that multi-agent chemotherapy may have better survival outcomes compared to single-agent chemotherapy in this age group.
Article
Surgery
Richard J. Straker, Danny H. J. Heo, Adrienne B. Shannon, Douglas L. Fraker, Skandan Shanmugan, Charles J. Schneider, Najjia N. Mahmoud, John T. Miura, Giorgos C. Karakousis
Summary: A predictive risk-score model can identify a high-risk cohort of stage II colon cancer patients who are most likely to benefit from adjuvant systemic therapy.
Article
Multidisciplinary Sciences
Yaobin Lin, Lei Wang, Lingdong Shao, Xueqing Zhang, Huaqin Lin, Youjia Wang, Junxin Wu
Summary: A study on the clinical efficacy of adjuvant external beam radiotherapy for patients with pathologic stage T4b sigmoid colon cancer found that patients who received adjuvant EBRT had a significantly longer median overall survival compared to those who did not receive radiation therapy. Age, serum carcinoembryonic antigen (CEA) level, perineural invasion, lymph node dissection (LND) number, and adjuvant EBRT were identified as independent factors associated with overall survival. A risk-stratification model was developed to predict the outcomes of high-risk patients based on specific factors.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Kexuan Li, Fuqiang Zhao, Yuchen Guo, Qingbin Wu, Shuangling Luo, Junling Zhang, Heli Li, Shidong Hu, Bin Wu, Guole Lin, Huizhong Qiu, Beizhan Niu, Xiyu Sun, Lai Xu, Junyang Lu, Xiaohui Du, Zheng Wang, Xin Wang, Liang Kang, Ziqiang Wang, Quan Wang, Qian Liu, Yi Xiao
Summary: The study aims to analyze the benefit of adjuvant chemotherapy in high-risk stage II colon cancer patients and the impact of high-risk factors on the prognostic effect of adjuvant chemotherapy.
Article
Oncology
Qiangkang Lin, Huizhen Zhou, Si Shi, Jixu Lin, Wangxin Yan
Summary: The aim of this study was to investigate the survival benefit of adjuvant chemotherapy in patients with colon cancer with the solitary tumor deposit (TD). The study found that adjuvant chemotherapy administration significantly improved overall survival (OS) and colon cancer-specific survival (CSS) in these patients.
FRONTIERS IN ONCOLOGY
(2022)